PALISADE Follow-on Study (ARC004)

Completed · Phase 3 · Has a placebo group

Conditions studied: Peanut Allergy

In brief

The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.

Key facts

Study ID
NCT02993107
Run by
Aimmune Therapeutics, Inc.
People needed
388
Starts
2016-12-29
Expected to finish
2019-05-31
Last updated by the study team
2022-03-17

Who can join

Age: 4 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.